Uppsala, 2 June 2026
Probingon AB announces that Fat Intrabody Communication (FAT-IBC), the company’s core platform technology, has been selected by the Royal Swedish Academy of Engineering Sciences (IVA) for their 2026 List for Research Impact. The IVA List recognises Swedish research with demonstrated potential for near-term societal and commercial impact. FAT-IBC is one of a small number of technologies selected across all scientific disciplines.
The technology
FAT-IBC is a communication platform that uses the body’s own tissue as a data channel, enabling implanted medical devices to exchange data in real time across distributed sites inside the body. No existing wireless standard achieves this reliably in a clinical implant environment. FAT-IBC provides the connectivity layer that makes genuinely distributed in-body architectures possible, and with them, a new generation of predictive, closed-loop implantable therapy.
Where today’s neuromodulation implants deliver stimulation based on pre-set parameters, a distributed FAT-IBC-enabled architecture allows sensing and stimulation to work together continuously, adapting therapy before symptoms break through rather than responding after the fact. Chronic pain and spinal cord injury rehabilitation are the primary clinical validation pathways, with applicability across neuromodulation therapy areas where distributed closed-loop control would improve patient outcomes.
The technology has reached Technology Readiness Level 6, validated in a relevant environment, at Uppsala University’s Microwaves in Medical Engineering Group at the Ångström Laboratory.
Commercial pathway
Probingon AB is the commercial vehicle for FAT-IBC, taking the technology from TRL 5 through to market via OEM licensing and distribution partnerships. Rather than developing a single end-use device, Probingon is building the enabling layer that next-generation implantable therapy systems can build on, a platform model with applicability across the neuromodulation industry.
The company is actively developing partnerships with neuromodulation manufacturers, clinical institutions, and strategic investors.
Acknowledgement
Probingon congratulates Associate Professor Robin Augustine, CTO and scientific principal investigator, and the entire Microwaves in Medical Engineering Group at Uppsala University for this recognition. More than a decade of foundational research has brought FAT-IBC to this milestone. The IVA selection is a testament to the scientific rigour and translational vision that has defined the MMG programme throughout.
About Probingon AB
Probingon AB is a MedTech company based in Uppsala, Sweden, commercialising platform communication technology for implantable medical devices. The company operates as the commercial partner to Uppsala University’s Microwaves in Medical Engineering Group, translating validated research into licensable technology for the global neuromodulation market.
For partnership and investment enquiries, contact:
Read the IVA listing: https://www.iva.se/det-iva-gor/utmarkelser/iva-listan/implantat-som-samarbetar-vid-smarta-och-sci/